STOCKHOLM, Jan. 13, 2021 /PRNewswire/ — On Tuesday January 12th, in Mother nature Communications, solid preclinical benefits for a new COVID-19 vaccine, created by the crew of Prof. Salanti from University of Copenhagen, ExpreS2ion Biotech, its joint venture husband or wife AdaptVac and the Avert-nCoV consortium, was released. Based mostly on these outcomes, a scientific trial application (CTA) for a scientific Period I/II research for the COVID-19 vaccine has been submitted.
About the preclinical outcomes
Readouts from the data display that ABNCoV2 has the prospective to be the very best-in-course COVID-19 vaccine with a far more than 100-fold increased stage of neutralizing antibodies in comparison with released preclinical animal information from at the moment approved COVID-19 vaccines, this sort of as Pfizer-BioNTech’s, Moderna’s, and AstraZeneca-Oxford’s vaccines. The total paper is obtainable on the web and can be browse listed here.
About the CTA
The Medical trial software (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) dependent COVID-19 vaccine was submitted to the Central Committee on Analysis Involving Human Subjects (CCMO) in the Netherlands very last week. It is anticipated to be approved less than a COVID-19 rapidly-keep track of evaluate development. This can be found as yet another substantial milestone adhering to the November 2020 announcement of the thriving GMP manufacturing of the vaccine. ExpreS2ion expects to existing preliminary scientific Phase I/IIa outcomes ahead of stop of Q1 2021.
Due to the fact March 2020, Attana has been assisting the crew of Prof. Ali Salanti at the College of Copenhagen in the improvement of this COVID-19 vaccine with two of Attana’s QCM Biosensors combined with investigation intelligence. As can be seen in the paper printed, Attana’s know-how has foremost been employed to assess kinetic interactions concerning RBD antigens and CLP-RBD to hACE2. Also, Attana and ExpreS2ion lately set up a strategic partnership including a supply arrangement of proteins. In addition, Attana know-how has been utilized to excellent control the vaccine for the IND submission.
Attana CEO Teodor Aastrup remarks:
“I am thrilled for our companions sake and for the future of vaccine improvement and want to congratulate all get-togethers included for achieving such thrilling final results. I am now hunting ahead to discover this collaboration even further and to hopefully function far more intently with equally Prof. Salanti and the crew at ExpreS2ion in the close to time future.”
For more details, please make contact with:
+46 () 8 674 57 00
The Board of directors for Attana think about that the data in this push launch is not probably to have a major outcome on the share price but is of general interest for the shareholders and that’s why ought to be communicated.
Attana was launched in 2002 with the eyesight of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has designed proprietary label free of charge biosensors for biochemical, crude, sera, and mobile-primarily based assays and the Attana Virus Analytics (AVA) system, a proprietary in-vitro diagnostics (IVD) device. Attana merchandise and investigation expert services are utilized by Major Pharma, biotech organizations and educational establishments inside of the everyday living sciences. To master far more about our most current providers and solutions, remember to visit www.attana.se or speak to [email protected].
This information was introduced to you by Cision http://news.cision.com
The next data files are obtainable for download: